Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Innovation Council · Running

ComfyCell ComfyCell: Novel Bionic Bioreactor for Industrial Stem and Immune Cell Manufacturing

Coordinator
Biothrust GmbH, Germany
Runs
1 September 2025 to 31 August 2027
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101218518

What the project is doing

In the project's own words, from its summary on CORDIS.

Stem and immune cell therapies are transforming modern medicine, offering new treatments for conditions like cancer, neurodegenerative diseases, and autoimmune disorders. Leveraging cells such as induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), Natural Killer (NK) cells, and T-cells, these therapies hold the potential to address diseases affecting hundreds of millions worldwide. However, the inability to scale the production of these cells presents a major bottleneck in making these life-saving treatments accessible.

Stem and immune cells are highly sensitive, struggling with conventional manufacturing processes due to their intolerance to high shear forces, nutrient supply fluctuations, and shifts in oxygen and pH levels. Despite the significant medical advancements, no scalable solution currently exists for industrial production of these cells. iPSC, NK cell, and T-cell cultivation is typically limited to small volumes (2L), and existing techniques rely on outdated bioreactor technologies initially designed for more robust cells.

Approaches like conventional stirred tank reactors (STRs), wave bags, and vertical wheel bioreactors introduce high shear forces or require labour-intensive reconfiguration, making them inadequate for industrial stem and immune cell manufacturing. BioThrust’s ComfyCell bioreactor is designed to address this challenge, offering a revolutionary solution for cultivating sensitive stem and immune cells at industrial scales.

As the first bioreactor to simulate the natural environment of these delicate cells, ComfyCell enables more efficient, high-yield production which is urgently desired by the market. By securing EIC Accelerator funding, BioThrust will be able to validate ComfyCell’s scalability and performance through pilot programs in industrial scales, incentivizing early adopters with cost-saving opportunities and valuable case studies.

Topics

Who is involved

OrganisationCityCountryRole
Biothrust GmbHAachenGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI